Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

915
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
915
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.1K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.1K
Glaucoma: Overview01:25

Glaucoma: Overview

1.2K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.2K
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

174
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
174
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

264
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
264

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structure and function of the retinal pigment epithelium.

Handbook of clinical neurology·2026
Same author

Patterns of Inflammation in Experimental Autoimmune Uveitis and Their Correlation to Optical Coherence Tomography Findings in Human Uveitis.

International journal of molecular sciences·2026
Same author

Immunology of Uveitis - From Bench to Bedside.

Klinische Monatsblatter fur Augenheilkunde·2026
Same author

Immunopathology of the Outer Retina: Crosstalk With the Immune System.

American journal of ophthalmology·2026
Same author

Case Report: Treating one autoimmune disease induces another: the paradox of TNF-alpha inhibitor therapies.

Frontiers in immunology·2025
Same author

A novel platform for engineered AAV-based vaccines.

Molecular therapy. Methods & clinical development·2025
Same journal

The interaction between inflammation and estrogen in adenomyosis : from molecular mechanisms to therapeutic strategies.

Seminars in immunopathology·2026
Same journal

The complex of gut microbial metabolites and sex hormones in Alzheimer's disease.

Seminars in immunopathology·2026
Same journal

Endometrial pathophysiology and pregnancy: from mechanism to intervention.

Seminars in immunopathology·2026
Same journal

Advances in understanding the dual roles of testicular immune responses: From immune privilege to inflammation.

Seminars in immunopathology·2026
Same journal

Climate change-associated heat extremes and immune dysregulation: emerging links with autoimmunity, allergy, and infectious diseases.

Seminars in immunopathology·2026
Same journal

The cancer-microbiome axis: Mechanisms and emerging therapeutic strategies.

Seminars in immunopathology·2026
See all related articles

Related Experiment Video

Updated: Jan 6, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

5.9K

Resolution of uveitis.

Gerhild Wildner1, Maria Diedrichs-Möhring2

  • 1Section of Immunobiology, Department of Ophthalmology, University Hospital, LMU Munich, Mathildenstr, 8, 80336, Munich, Germany. Gerhild.Wildner@med.uni-muenchen.de.

Seminars in Immunopathology
|October 9, 2019
PubMed
Summary
This summary is machine-generated.

Autoimmune uveitis, an inflammatory eye disease, involves T cells attacking the eye. This study explores regulatory mechanisms in animal models and patients to control this sight-threatening condition.

Keywords:
AutoimmunityChemokinesCytokinesEyeImmune privilegeT cells

More Related Videos

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

3.1K
Iris Fixation via External Pentagram Suturing
05:22

Iris Fixation via External Pentagram Suturing

Published on: May 5, 2022

1.7K

Related Experiment Videos

Last Updated: Jan 6, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

5.9K
Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

3.1K
Iris Fixation via External Pentagram Suturing
05:22

Iris Fixation via External Pentagram Suturing

Published on: May 5, 2022

1.7K

Area of Science:

  • Ophthalmology
  • Immunology
  • Autoimmune Diseases

Background:

  • Autoimmune uveitis is a rare, sight-threatening condition causing intraocular inflammation.
  • It presents diverse clinical phenotypes driven by distinct immune responses.
  • T cells recognizing intraocular antigens initiate the inflammatory cascade, leading to tissue damage.

Purpose of the Study:

  • To elucidate the regulatory mechanisms governing autoimmune uveitis.
  • To investigate immune privilege and novel regulatory features in controlling ocular inflammation.
  • To compare regulatory mechanisms in experimental animal models and human patients.

Main Methods:

  • Analysis of regulatory mechanisms in experimental autoimmune uveitis models.
  • Examination of peripheral lymphocytes from human patients with uveitis.
  • Identification of suppressive cytokines and regulatory T cell populations.

Main Results:

  • Ocular immune privilege and blood-eye barriers normally prevent inflammation.
  • Upon disease induction, regulatory mechanisms including Treg cells and cytokines are activated.
  • These mechanisms aim to downregulate ocular inflammation and prevent disease chronicity.

Conclusions:

  • Understanding uveitis regulation is crucial for developing targeted therapies.
  • Novel regulatory pathways offer potential for preventing relapses and chronicity.
  • Further research in animal models and patient studies can advance treatment strategies.